Probiotics for the prevention of beta cell autoimmunity in children at genetic risk of type 1 diabetes--the PRODIA study.
The final aim of the PRODIA study is to determine whether the use of probiotics during the first 6 months of life decreases the appearance of type 1 diabetes mellitus (T1DM)-associated autoantibodies in children with genetic risk for T1DM. A pilot study including 200 subjects was planned to show whether the use of probiotics during the first 6 months of life is safe and feasible. The prevalence of autoantibodies among the study subjects at 6, 12, and 24 months of age was at levels close to the expected and the clinical follow-up did not either indicate problems in the feasibility of the study.
Ljungberg
Martin
M
Centre of Clinical Experimental Research, Division of Pediatrics and Diabetes Research Centre, Department of Molecular and Clinical Medicine, Faculty of Health Sciences, Linköping University, S-581 85 Linköping, Sweden. martin.ljungberg@imk.liu.se
Korpela
Riita
R
Ilonen
Jorma
J
Ludvigsson
Johnny
J
Vaarala
Outi
O
D001323:Autoantibodies / Q000097:blood / Q000276:immunology; D015551:Autoimmunity; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000453:epidemiology / Q000235:genetics* / Q000276:immunology*; D004311:Double-Blind Method; D005240:Feasibility Studies; D020022:Genetic Predisposition to Disease; D006801:Humans; D007223:Infant; D050417:Insulin-Secreting Cells / Q000276:immunology*; D010865:Pilot Projects; D015995:Prevalence; D019936:Probiotics / Q000008:administration & dosage* / Q000009:adverse effects; D012307:Risk Factors; D013997:Time Factors
D001323:Autoantibodies